Latest News and Press Releases

UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see attached file. For additional information, please contact:  Monica Wallter, CEO LIDDS, +46...

UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see below link or PDF...

An interview with Professor Laurence Klotz, one of the LPC-004 study investigators was done in connection to the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19 in which he...

JULI – SEPTEMBER 2019Nettoomsättningen uppgick till 0,0 (7,8) MSEKKostnaderna uppgick till -2,8 (-2,5) MSEKResultatet före och efter skatt uppgick till -2,8 (5,4) MSEKResultat per aktie uppgick till...

UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary...

The board of directors of LIDDS AB has decided to carry out a directed issue of 562,500 shares at a subscription price of SEK 16 per share. LIDDS will through the directed share issue receive proceeds...

UPPSALA, SWEDEN – LIDDS AB (publ) Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA....

UPPSALA, SWEDEN – LIDDS AB (publ) has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. Previously the phase I study is approved in Sweden and Denmark. The...

UPPSALA, SWEDEN. LIDDS AB (publ) – Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca® Depot in prostate cancer patients than anticipated. In half of the...

UPPSALA, SWEDEN. LIDDS AB (publ) – Due to a technical error by a market data provider, Wikow Invest was removed as largest shareholder in Top 10 tables at several trading and information sites over...